---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-001683"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:04:43.476526+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences reports Q2 2022 net loss of $2.4M, announces 1-for-15 reverse stock split to regain Nasdaq compliance

## Summary
- Net loss $2.4M ($0.87/share) in Q2 2022 vs $2.3M ($1.45/share) in Q2 2021; operating expenses $2.4M.
- Cash and investments $21.3M at June 30, 2022, down from $25.6M at Dec 31, 2021; expected to fund operations through end of 2023.
- 15-for-1 reverse stock split effective August 10, 2022 to improve marketability and regain Nasdaq compliance; shares reduced from 42.6M to ~2.8M.
- CAReS study of ART27.13 progresses to fourth cohort (650 mcg); Phase 2b enrollment expected Q4 2022.
- Preclinical data for ART26.12 shows efficacy in chemotherapy-induced neuropathy models.

## SEC filing metadata
- accession: 0001640334-22-001683
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033422001683/0001640334-22-001683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033422001683/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-001683
- JSON: https://secwatch.observer/filing/0001640334-22-001683.json
- Plain text: https://secwatch.observer/filing/0001640334-22-001683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.